Anti-blood Clotting Activity Screening Service

Anti-blood Clotting Activity Screening Service at CD BioGlyco

Most marine glycans have significant anti-blood clotting activity. CD BioGlyco offers a multi-faceted anti-blood clotting activity screening service according to coagulation system screening assays.

We explore the anti-blood clotting activity of marine glycans and glycoproteins based on two pathways, endogenous and exogenous, and three stages: formation of plasminogen activator, activation of plasminogen into thrombin, and conversion of fibrinogen into gel-like fibrin, respectively. Among them, we provide an in vitro anti-blood clotting activity assay combined with scanning electron microscopy (STM) or atomic force microscopy (AFM) to observe their anti-blood clotting activity.

We offer tests that include, but are not limited to:

Fig.1 Anti-blood clotting activity screening services. (CD BioGlyco)

Publication

Technology: Thromboplastin time assay

Journal: Marine Drugs

IF: 5.4

Published: 2018

Results: Seaweed polysaccharides (SPm) were isolated from brown algae and their polymeric repeat units and anticoagulant properties in vitro and in vivo have been studied in this study. SPm is a sulfated polysaccharide consisting mainly of two linked α-1 rhamnose residues and three linked α-1 rhamnose residues with sulfate moieties. Small amounts of xylose and glucuronic acid were present as β-d-Xylp(4SO₄)-(1→) and β-d-GlcA-(1→). Effective prolongation of the clotting time as well as strong anticoagulant activity in vitro and in vivo of SPm could be found by activation of partial thromboplastin time. Next, the fibrinogen and thrombolytic properties of SPm were evaluated by measuring rat plasma with fibrinogen activator inhibitor-1, fibrin degradation products, D-dimer, and clot lysis rate. The results showed that SPm had high fibrinogen and catabolic capacity and thrombolytic properties. These results suggest that SPm has potential as a novel anticoagulant.

Fig.2 Anticoagulant activity in vivo of SPm. (Liu, et al., 2018)

Applications

• Anti-blood clotting activity screening technology can be used to develop coagulants from marine glycans and glycoproteins.
• Anti-blood clotting screening technology can be used to explore the anticoagulant activity of a wide range of substances.
• The anti-blood clotting activity screening technology can be used to aid in the development of marine glycan-based anticoagulant drugs.

Advantages

• We are committed to providing high-quality, reliable bioactivity testing solutions to ensure that we achieve the desired results for our clients, following the trend of technological development.
• We have the world's leading bioactivity testing technology and provide a wide range of products with testing services.
• We offer custom bioactivity assay solutions based on our clients' scientific needs, as well as comprehensive data analysis.

CD BioGlyco is an expert in the field of Marine Glycans and Glycoproteins Analysis with many years of experience, we have advanced technology and are committed to providing high-quality custom marine glycans and glycoproteins bioactivity analysis services. We invite you to contact us and we would be delighted to have the opportunity to support you.